Application Nr Approved Date Route Status External Links
ANDA076187 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Hypothyroidism: Levothyroxine Sodium Tablets Are Indicated As A Replacement Therapy In Primary (thyroidal), Secondary (pituitary), And Tertiary (hypothalamic) Congenital Or Acquired Hypothyroidism. Pituitary Thyrotropin (thyroid-Stimulating Hormone, Tsh) Suppression: Levothyroxine Sodium Tablets Are Indicated As An Adjunct To Surgery And Radioiodine Therapy In The Management Of Thyrotropin-Dependent Well-Differentiated Thyroid Cancer. Limitations Of Use: Levothyroxine Sodium Tablets Are Not Indicated For Suppression Of Benign Thyroid Nodules And Nontoxic Diffuse Goiter In Iodine-Sufficient Patients As There Are No Clinical Benefits And Overtreatment With Levothyroxine Sodium Tablets May Induce Hyperthyroidism [see Warnings And Precautions (5.4) ]. Levothyroxine Sodium Tablets Are Not Indicated For Treatment Of Hypothyroidism During The Recovery Phase Of Subacute Thyroiditis. Levothyroxine Sodium Tablets Are Levothyroxine Sodium (t4) Indicated For: Hypothyroidism: As Replacement Therapy In Primary (thyroidal), Secondary (pituitary), And Tertiary (hypothalamic) Congenital Or Acquired Hypothyroidism. ( 1 ) Pituitary Thyrotropin (thyroid-Stimulating Hormone, Tsh) Suppression: As An Adjunct To Surgery And Radioiodine Therapy In The Management Of Thyrotropin-Dependent Well-Differentiated Thyroid Cancer. ( 1 ) Limitations Of Use: Not Indicated For Suppression Of Benign Thyroid Nodules And Nontoxic Diffuse Goiter In Iodine-Sufficient Patients. Not Indicated For Treatment Of Hypothyroidism During The Recovery Phase Of Subacute Thyroiditis.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Levothyroxine Sodium LEVOTHYROXINE SODIUM ZINC3830993

Comments